Cytogen Stock Net Income

217330 Stock  KRW 9,220  230.00  2.43%   
Cytogen fundamentals help investors to digest information that contributes to Cytogen's financial success or failures. It also enables traders to predict the movement of Cytogen Stock. The fundamental analysis module provides a way to measure Cytogen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytogen stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cytogen Company Net Income Analysis

Cytogen's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Cytogen Net Income

    
  (10.87 B)  
Most of Cytogen's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytogen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, Cytogen reported net income of (10.87 Billion). This is 3285.22% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology & Medical Research industry. The net income for all Republic of Korea stocks is significantly higher than that of the company.

Cytogen Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytogen's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytogen could also be used in its relative valuation, which is a method of valuing Cytogen by comparing valuation metrics of similar companies.
Cytogen is currently under evaluation in net income category among its peers.

Cytogen Fundamentals

About Cytogen Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cytogen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytogen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Cytogen Stock

Cytogen financial ratios help investors to determine whether Cytogen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cytogen with respect to the benefits of owning Cytogen security.